Kite Phama Inc KITE shares are trading higher by $7.36 (14 percent) at $59.44 in Monday's session. The catalyst for the rally are results from its Kite/NCI Anti-CD19 Car T-cell therapy that demonstrated durable complete remissions in over half of the advanced non-Hodgkin lymphoma patients in the study.
After a higher open, it retreated but found support just under Friday's close ($52.08), reaching $51.76 before resuming its move higher.
So far, it has reached $59.65 and has continued to make new highs for the day. The issue has not traded over $60 since January 19, when it peaked at $60.72.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.